Pluristem Therapeutics Expands Presence in Sports Medicine Market

Pluristem Therapeutics, placenta-based cell therapies company, has announced the initiation of a Phase I clinical trial of PLX-PAD cells as a treatment for patients with tendon injures.

Advertisement

The study will determine the efficacy of the cells to treat rotator cuff tears necessitating arthroscopic repair.

Pluristem has also announced that PLX-PAD cells are intended to grow the company’s presence in the sports medicine and orthopedic markets.

More Articles on Sports Medicine:
Manhattan Orthopedic Care Releases NBA Injury Infographic
Drs. Robert Zura, Claude Moorman Perform Successful Surgery on Duke’s Seth Curry
Methodist Willowbrook Hospital Opens Sports Medicine Center

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.